FIELD: medicine.
SUBSTANCE: invention relates to molecular biology and oncology. Test system for predicting the development of metastases in patients with gastric cancer on the basis of determining the number of copies of HV2 mtDNA, containing highly specific primers for the HV2 and B2M genes with the concentration of 1800 nM each in an aqueous solution, is proposed.
EFFECT: invention provides a simple, low-cost and accurate test system with highly specific primers for predicting the development of metastases in patients with gastric cancer.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF METASTASES DEVELOPMENT IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2624505C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF GASTRIC CANCER OF DIFFERENT HISTOLOGICAL TYPES | 2015 |
|
RU2613139C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSTICS OF LUNG CANCER ON BASIS OF CHANGING COPY NUMBER OF MTDNA HV2 LOCUS | 2018 |
|
RU2678227C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF METASTASES IN REGIONAL LYMPH NODES IN PATIENTS WITH GASTRIC ADENOCARCINOMA | 2017 |
|
RU2661600C1 |
| ESSC-TIPE-1TEST-SYSTEM FOR MOLECULAR-GENETIC TYPING OF SQUAMOUS OESOPHAGEAL CANCER | 2020 |
|
RU2742468C1 |
| MINIMALLY INVASIVE METHOD FOR DETECTING SENSITIVITY OF RECTAL TUMOUR TO RADIATION THERAPY BASED ON CHANGE IN ABUNDANCE OF N2AX AND RBBP8 GENES | 2019 |
|
RU2740576C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSING METASTATIC LESIONS OF REGIONAL LYMPH NODES IN PATIENTS WITH CERVICAL CANCER BASED ON THE COPY NUMBER OF THE CCND1 AND PPARGC1A GENES | 2021 |
|
RU2766774C1 |
| METHOD OF PREDICTING METASTASIS OF STOMACH CANCER TUMORS | 2021 |
|
RU2806432C2 |
| TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE | 2017 |
|
RU2661599C1 |
| METHOD FOR PREDICTION OF DEVELOPING METASTASES IN UTERINE CANCER PATIENTS BASED ON ANALYSIS OF MAGEA1, MAGEB2 AND PRAME1 GENE EXPRESSION | 2018 |
|
RU2698895C1 |
